A phase II study of durvalumab (MEDI 4736) maintenance in frail limited disease small cell lung cancer patients after thoracic chemoradiotherapy (CRT)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 May 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

27 Mar 2023 Planned End Date changed from 15 Nov 2028 to 30 Mar 2029.
27 Mar 2023 Planned primary completion date changed from 15 Nov 2026 to 15 Jan 2027.
16 Jan 2023 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com